Picture a wellness-clinic menu that lists “compounded Ipamorelin” next to sleep, recovery, and body-composition packages. The brochure treats the name like a finished therapy. The everyday question is narrower: when FDA asked its Pharmacy Compounding Advisory Committee whether Ipamorelin belongs on the 503A bulk-substances list, what did the agency’s own briefing say?
That question is about regulation and evidence quality, not about how to buy or use a research vial. Catalog research listings remain research materials. They are not an approved medicine.
What FDA put in front of its advisers
Ipamorelin is a short peptide studied as a selective ghrelin-receptor agonist. In October 2024, FDA’s Pharmacy Compounding Advisory Committee met to consider whether Ipamorelin free base and Ipamorelin acetate should be added to the 503A Bulks List. The public meeting materials and FDA’s evaluation memo are posted on FDA.gov.
FDA’s August 2024 briefing for that meeting proposed that neither form be placed on the list. The memo weighed physical and chemical characterization, historical compounding use, evidence of effectiveness, and safety. On characterization, reviewers said critical data such as impurities, aggregates, and bacterial endotoxins were missing or incomplete in public literature and nomination packages. On effectiveness, they concluded that evidence for growth-hormone deficiency and postoperative ileus was limited for any route, and that they found no data supporting effectiveness of the nominated subcutaneous route for those conditions. On safety, they flagged immunogenicity concerns for injectable routes when peptides can aggregate or carry peptide-related impurities, and they noted that a published postoperative-ileus study reported adverse events including electrolyte changes, nausea, and death, while stating it was unclear whether the deaths were related to Ipamorelin.
Separately, FDA’s public page on bulk substances that may present significant safety risks still lists Ipamorelin acetate under the 503B interim Category 2 policy. That entry cites immunogenicity risk from aggregation or impurities, unnatural amino acids that complicate peptide characterization, and the same published intravenous gastric-motility study that reported serious adverse events including death. The page is a regulatory-risk note, not a product endorsement.
What a clinic menu does not settle
Wellness marketing and research-catalog names can make a compounded listing sound continuous with hospital research. FDA’s briefing drew a different line: growth-hormone deficiency and postoperative ileus are serious conditions that already have FDA-approved options, professional guidelines do not discuss Ipamorelin for those uses, and the agency lacked the characterization and safety data it wanted for adding the substance to the 503A list.
An earlier Everyday Brief story covered volunteer growth-hormone-pulse studies and the postoperative-ileus efficacy program on their own terms.
What to do with the menu. If a clinic offers compounded Ipamorelin, ask which medical condition is being treated, which human study supports that claim for the exact product and route, and whether the substance appears on FDA’s compounding safety-risk materials. Vague answers are useful information. Bring the question to a clinician who already knows your other medicines and lab history rather than treating a menu item as settled care.
Not medical advice.
Sources
- FDA briefing (Aug 19, 2024): Evaluation of Ipamorelin-related bulk drug substances for the 503A Bulks List
- FDA Pharmacy Compounding Advisory Committee meeting page, October 29, 2024
- FDA compounding safety-risk list: Ipamorelin acetate entry (503B Category 2)
Related reading
- Ipamorelin secretagogue ads and human trial evidence
- How to read FDA bulk-compounding safety notes
- What FDA says about compounded drugs now
By The Everyday Brief. AI-assisted drafting with human editorial review. Sources fetched 2026-10-12 PT. Not medical advice.